| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10017950 | HBV | ENSG00000229314.6 | protein_coding | ORM1 | No | No | 5004 | P02763 |
| TVIS10059146 | HBV | ENSG00000229314.6 | protein_coding | ORM1 | No | No | 5004 | P02763 |
| TVIS10059148 | HBV | ENSG00000229314.6 | protein_coding | ORM1 | No | No | 5004 | P02763 |
| TVIS10059150 | HBV | ENSG00000229314.6 | protein_coding | ORM1 | No | No | 5004 | P02763 |
| TVIS10059149 | HBV | ENSG00000229314.6 | protein_coding | ORM1 | No | No | 5004 | P02763 |
| TVIS10059147 | HBV | ENSG00000229314.6 | protein_coding | ORM1 | No | No | 5004 | P02763 |
| TVIS10060220 | HBV | ENSG00000229314.6 | protein_coding | ORM1 | No | No | 5004 | P02763 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | ORM1 |
|---|---|
| DrugBank ID | DB00396 |
| Drug Name | Progesterone |
| Target ID | BE0000925 |
| UniProt ID | P02763 |
| Regulation Type | binder |
| PubMed IDs | 16901474; 12204624; 9305808; 12445481 |
| Citations | Albani JR: Progesterone binding to the tryptophan residues of human alpha1-acid glycoprotein. Carbohydr Res. 2006 Nov 6;341(15):2557-64. Epub 2006 Aug 8.@@De Ceukeleire M, Albani JR: Interaction between carbohydrate residues of alpha(1)-acid glycoprotein (orosomucoid) and progesterone. A fluorescence study. Carbohydr Res. 2002 Sep 3;337(15):1405-10.@@Albani JR: Binding effect of progesterone on the dynamics of alpha1-acid glycoprotein. Biochim Biophys Acta. 1997 Aug 29;1336(2):349-59.@@Nishi K, Sakai N, Komine Y, Maruyama T, Halsall HB, Otagiri M: Structural and drug-binding properties of alpha(1)-acid glycoprotein in reverse micelles. Biochim Biophys Acta. 2002 Dec 16;1601(2):185-91. |
| Groups | Approved; Vet_approved |
| Direct Classification | Gluco/mineralocorticoids, progestogins and derivatives |
| SMILES | [H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C |
| Pathways | Adrenal Hyperplasia Type 3 or Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency; Apparent Mineralocorticoid Excess Syndrome; Congenital Lipoid Adrenal Hyperplasia (CLAH) or Lipoid CAH; 3-beta-Hydroxysteroid Dehydrogenase Deficiency; Corticosterone Methyl Oxidase I Deficiency (CMO I); 11-beta-Hydroxylase Deficiency (CYP11B1); Steroidogenesis; Adrenal Hyperplasia Type 5 or Congenital Adrenal Hyperplasia Due to 17 alpha-Hydroxylase Deficiency; 17-alpha-Hydroxylase Deficiency (CYP17); Corticosterone Methyl Oxidase II Deficiency (CMO II); 21-Hydroxylase Deficiency (CYP21) |
| PharmGKB | PA451123 |
| ChEMBL | CHEMBL103 |
